
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp has demonstrated positive momentum in its revenue performance, particularly with glaucoma products, as evidenced by a 45% increase in glaucoma revenue to $110 million in 3Q25, surpassing consensus estimates. The company's operational efficiency is reflected in an improved operating margin of (7.0%), significantly better than the previous year's (8.1%) margin and consensus expectations. Additionally, the Corneal Health segment has showcased robust growth with a CAGR of approximately 15.2% globally since 2020, indicating strong market positioning and future potential for products like Epioxa, as adoption rates are anticipated to rise significantly in the coming years.
Bears say
Glaukos Corp faces a negative outlook primarily due to lower-than-expected market growth for minimally invasive glaucoma surgeries (MIGS) and the anticipated slow uptake of its novel products, such as iDose TR and the iStent infinite. Additionally, the company's sales have demonstrated vulnerability, with a reported 4.7% decline in legacy surgical glaucoma revenues, alongside concerns of declining Corneal Health revenues driven by the transition to Epioxa. The company also faces risks related to potential changes in the reimbursement landscape and increased competition, which could hinder future revenue growth and market share.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares